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Human African trypanosomiasis is a debilitating disease prevalent in rural sub-Saharan Africa. Control of this disease almost
exclusively relies on chemotherapy that should be driven by accurate diagnosis, given the unacceptable toxicity of the few available
drugs.Unfortunately, the available diagnostics are characterised by low sensitivities due tothe inherent low parasitaemia in natural
infections. Demonstration of the trypanosomes in body ﬂuids, which is a prerequisite before treatment, often follows complex
algorithms. In this paper, we review the available diagnostics and explore recent advances towards development of novel point-of-
care diagnostic tests.
1.Introduction
Human African trypanosomiasis (HAT), also known as
sleeping sickness, is a parasitic disease caused by ﬂagellated
protozoa of the genus Trypanosoma. Transmitted by the
Tsetse ﬂy (Glossina sp), HAT is endemic in rural sub-Saharan
Africa that oﬀers suitable habitat for the vectors, mainly
riverineforestsandsavanna.Thediseaseoccursintwoforms,
namely, the chronic type attributed to T. brucei gambiense
(Gambian sleeping sickness) that is prevalent in central
and west Africa as well as the acute (Rhodesian) form due
to T. b. rhodesiense in east and southern Africa. HAT has
been a major public health problem since colonial times
when it wiped out entire villages in hard to reach areas of
Africa. This situation was reversed through vigorous mass
screening campaigns and vector control. However, during
the wave of political instability and civil strife that swept
sub-Saharan Africa in the later part of the last century, there
was an upsurge in HAT incidence. Out of the known 36
endemic countries, over 90% of the cases were reported from
Angola, Democratic Republic of Congo, southern Sudan and
Uganda. Presently, HAT incidence has registered a steady
decline over the past decade. Previous estimates indicated an
annual incidence of about 70,000 cases [1, 2]; in 2006, the
DRC had the highest incidence reported as 8,023 followed
by Angola (1,105) out of the overall 11,382 for that year
[3]. By 2009, the numbers had dwindled even further [4].
Although there may be underreporting, this trend indicates
that elimination of HAT is within reach, at least in a few
countries that continue to report no cases.
The disease is invariably fatal if left untreated and pro-
gresses through 2 stages: the early hemolymphatic stage,
also known as stage I and the late meningoencephalitic stage
(stage II) when the trypanosomes penetrate beyond the
blood-brain-barrier. In addition, HAT exhibits 2 distinct
forms associated with the causative subspecies: Trypanosoma
brucei gambiense infection manifests as a chronic condition
that claims its victims after several months, or even years.
On the other hand, T. b. rhodesiense causes an acute infection
that may kill patients within a few weeks [5]. HAT is among
the so-called neglected tropical diseases (NTDs) that aﬄict
rural poor communities in the developing world. In terms
of disability-adjusted life year (DALY) estimations, this
disease ranks high among other NTDs such as ascariasis,2 Journal of Tropical Medicine
schistosomiasis, leishmaniasis and hookworm infection [6,
7].Inanotherstudycarriedoutinanendemicareaofeastern
Uganda, the burden attributed to T. b. rhodesiense HAT was
reported to be only second to malaria, despite the former’s
relatively low incidence [8]. Mandatory and long durations
of hospitalization render HAT an important problem within
theusuallyresourcepoor healthfacilities,adding to logistical
requirements of the already constrained services.
Control of HAT largely relies on chemotherapy for which
there are only a few drugs, all associated with unacceptable
toxicity and complex treatment regimens. The drugs are par-
ticularly old, the latest regimen being NECT that combines
nifurtimox that is normally indicated for Chagas’ disease (T.
cruzi) and eﬂornithine, which was initially developed as an
anticancer agent. Presently, only one drug Fexinidazole is
in phase I clinical trials [9], while another compound (an
oxaborole) has recently passed proof of principle in exper-
imental infections [10]. The high toxicity of trypanocidal
drugs dictates that trypanosomes must be demonstrated and
the disease stage determined before any prescriptions can
be made (late stage disease requires drugs that can cross
the blood-brain-barrier). Indeed HAT case deﬁnition is by
demonstration of trypanosomes by microscopy in fresh or
stained body tissues, namely, blood, lymph, or cerebrospinal
ﬂuid (CSF). The available methods for this are tedious and
suﬀer low sensitivity [11]. Availability of serological screen-
ing methods is, therefore, important to identify individuals
on whom to execute the laborious parasitological methods.
For this, the Card Agglutination Test for Trypanosomiasis
(CATT) [12] has been a success story in diagnosis of T.
b. gambiense HAT. However, most T. b. rhodesiense do not
express the antigen on which the CATT is based. To date
thereisnoﬁeldadaptedserologicaltestforthisform,amajor
setback to screening in T. b. rhodesiense endemic areas.
The ﬁeld of diagnostics for HAT has largely lagged be-
hind; the tendency has been more of modiﬁcations of pre-
existing techniques than development of entirely new ones.
Here we review the available options and explore recent ad-
vances towards development of novel point-of-care diagno-
stics.
2. Available Approachesto HAT Diagnosis
Asnotedabove,HATcaseidentiﬁcationreliesondemonstra-
tion of trypanosomes in body ﬂuids. The major obstacle to
this is the characteristically low parasitaemia, especially in T.
b. gambiense HAT, necessitating concentration methods that
add to the complexity of the diagnosis. Serological screening,
therefore, plays a pivotal role in identifying individuals for
parasitological manipulations. The CATT [12] is the only
available test for this and is the entry point to all the diﬀerent
diagnostic algorithms that vary from country to country, or
even between regions of the same country depending on
availability of the diﬀerent parasitological tests as well as
personnel to execute them. The CATT is an antibody test
based on the LiTat 1.3 gene that is present in T. b. gambiense,
although some stocks from Cameroon could reportedly not
b ed e t e c t e dd u et oa b s e n c eo ft h i sg e n e[ 13]. Another report
indicated that some stocks may be missed when they do
not express the gene that is otherwise present [14]. The
classical CATT kit consists of lyophilised antigen supplied
in units of 50 tests, whose integrity relies on the cold chain.
The latest advance in this area has been development of a
thermostable version in units of 10 tests for wide coverage
of and practicality [15]. The shortcoming of CATT, like any
other antibody test, is that it does not necessarily indicate
active infection. In addition, false positives are common,
arising from cross reactivity with other pathogens including
malaria or even transient nonhuman infective trypanosomes
[12] that get inoculated into the bloodstream.
3.ParasitologicalMethods
Typically, all diagnostic algorithms start with CATT screen-
ing, followed by parasitological conﬁrmation and staging
[11, 16]. Available techniques have been extensively reviewed
elsewhere [11]. The Haematocrit Centrifugation Technique
(HCT) [17] is the test of choice for demonstration of
parasites since it concentrates trypanosomes at the buﬀy
coat area where they can be located by microscopy. The
detection limit of this method is 500 trypanosomes/mL of
blood [11]. This is no problem for T. b. rhodesiense that is
in many cases easily detectable from wet ﬁlms or stained
thick smears, but some T. b. gambiense cases could still be
missed due to low parasitaemia. Sensitivity of this method
can be improved by examining several capillaries from the
same patient. A more sensitive concentration method is the
mini-Anion Exchange Centrifugation Technique (mAECT)
that was adapted for ﬁeld use over 3 decades ago [18]. This
has subsequently been modiﬁed into formats that facilitate
easy assembly, execution, and subsequent visualisation of the
trypanosomes [19]. The kits are now produced and can be
ordered from the Institut Nationale de Recherche Biomed-
icale (INRB), in the DRC. Latest additions to trypanosome
concentration involve diﬀerential lysis of red blood cells to
leave behind intact trypanosomes and white cells, followed
by centrifugation. This greatly improves sensitivity; up to
3mL blood can be concentrated to a pellet that is used
to prepare smears that could be examined as wet or ﬁxed
and stained. For convenience, homemade or commercially
available lysis solutions can be used to process the sam-
ple (see http://www.ﬁnddiagnostics.org/programs/hat/ﬁnd
activities/parasite detection/parasite concentration).
4.ParasiteStaining
The stain of choice has for a long time been Giemsa,
few laboratories use ﬁeld stains for trypanosome diagnosis.
However during the 1990s, acridine orange was used as a
good alternative since it enables trypanosomes to ﬂuoresce
in presence of UV light. Thus, the quantitative buﬀyc o a t
technique was devised [20] and subsequently used albeit at
a low scale in screening programs. The major issue here was
the expensive microscope that was available then, coupled
with the requirement for a dark room, features that made
the technique nonfeasible at a typical treatment centre inJournal of Tropical Medicine 3
endemic countries. The Foundation for Innovative New
Diagnostics(FIND)hasrecentlyrevisitedthistechniqueand,
together with Carl Zeiss, developed a simple Primo Star
iLED microscope (Figure 1), which oﬀers options for both
ﬂuorescence and bright ﬁeld microscopy. The ultrabright
light-emitting diode (LED) technology exploited for this
microscopeprovidesacheap,long-lastinglightsource(diode
lifespan >10,000 hours). In addition, this microscope does
not require a dark room and can be solar-powered since
it consumes little energy. Besides, acridine orange typically
stains all nucleated cells, so the iLED microscope can be
applied to other haemoparasites that may coexist with HAT
in the same endemic areas. The iLED microscope is now
undergoing ﬁeld evaluation in Uganda and the DRC.
5.DiseaseStaging
This is a critical step in diagnosis that guides the choice of
treatment, given that drugs like pentamidin and suramin
cannot cross into the central nervous system in suﬃcient
amounts, and are, therefore, only prescribed for early (stage
I) disease. HAT staging relies on the lumbar puncture to
obtain CSF that is used to determine white blood cell counts,
which rise over 5/mm3 at onset of the late stage disease. Live
trypanosomes in the CSF are demonstrated after single [21]
or double centrifugation of CSF [22], where the motile para-
sites are located in the cell pellets. This method too has been
further developed into the modiﬁed single-centrifugation
(MSC) technique [19] to ease parasite detection, and kits can
be ordered from the INRB. Production of mAECT and MSC
kits in the DRC are fruits of collaborative eﬀorts between
the Institute of Tropical Medicine (ITM) in Antwerp, FIND
and INRB, a model for empowering endemic countries to
produce some of the vital supplies for the national control
programs.
6. CurrentandUpcoming Novel
MolecularDiagnostics
DNA-based diagnostic tests have been pursued since the
1980s when species-speciﬁc probes were ﬁrst described [23,
24]. Upon the advent of the polymerase chain reaction
(PCR) for in vitro DNA ampliﬁcation [25], species-speciﬁc
oligonucleotide primers were designed for detection of
trypanosomes [26, 27]. Since then, numerous targets within
the trypanosome genome have been explored [28], including
subspecies-speciﬁc PCRs that can detect T. b. gambiense or T.
b. rhodesiense [29–31].Themajorshortcomingwiththelatter
isthattheirtargetsaresingle-copygenes[29–31],suchthatin
several laboratories nested PCR is used [32–35] to maximise
chances to obtain signals. Therefore in areas where the
geographical distribution of the two forms of HAT is clearly
known, PCR aimed at multicopy targets should be preferred
for maximum sensitivity. As can be expected, PCR is a highly
sensitive and speciﬁc method for identiﬁcation of cases.
However, its requirement for well-equipped laboratories
coupled to a well-established cold chain to preserve reagents
inevitably dictates that PCR will for a long time be based at
reference laboratories far away from rural treatment centres.
Nevertheless, PCR remains invaluable for epidemiological
studies, including disease mapping and monitoring for drug
resistance for compounds whose markers are known.
The latest approach to reduce equipment requirements
for PCR was detection of products by oligochromatography
(OC), which eliminates the need for electrophoresis that
usually follows the thermocycling. For this, a PCR-OC test
targeting the 18S rRNA gene was developed and displayed
satisfactory sensitivity during the proof of principle [36].
PCR-OC still requires a thermocycler.
7. NucleicAcid-Based Ampliﬁcation (NASBA)
Another DNA ampliﬁcation method that can be coupled
to chromatography is the nucleic acid-based ampliﬁcation
( N A S B A )o fR N A[ 37]. This diﬀers from conventional PCR
in that it is run at isothermal conditions, therefore, replacing
the thermocycler with much less expensive equipment (a
heatingblockorwaterbathissuﬃcient).Thisisanadvantage
that would bring NASBA closer to the ﬁeld situation.
However, its major shortcoming is the need for elaborate
RNA puriﬁcation procedures; such facilities for puriﬁcation
and preservation of the characteristically fragile RNA remain
major obstacles for its use in the ﬁeld.
NASBA for trypanosome DNA ampliﬁcation was ﬁrst
describedinrealtime[38]andthenextendedtovisualisation
of the ampliﬁcation product by OC [39]. The developed
NASBA-OC was designed for the same target as PCR-OC but
it ampliﬁes the rRNA itself, thus is likely to be more sensitive
since numerous RNA copies can be transcribed from a
single gene. PCR and NASBA-OC were recently evaluated on
clinical samples from endemic countries [40]. Indeed, the
latter was more sensitive, as would be theoretically expected.
The use of these techniques at least at reference laboratories
will depend on how readily they are demanded by end users.
Indeed, PCR-OC is available on demand (Figure 2), while a
related test for Leishmaniasis (PCR-OC Leish) was commer-
cializedover2yearsagoandisnowmarketedasLeishOligoC
(http://www.corisbio.com/Products/Leishmania.php). Due
to over cost, there are many challenges to commercialization
of NASBA-OC, a typical example of obstacles to develop-
ment of interventions for diseases that aﬀect the poor. PCR
and NASBA-OC tests for HAT and Leishmaniasis were
developed in an EU funded collaborative project “TRYLEI-
DIAG” under the EUFP7 program.
8. TheLoop-MediatedIsothermalAmpliﬁcation
(LAMP) Technique
Among the latest developments in the area of molecular
diagnostics is the loop-mediated isothermal ampliﬁcation
(LAMP) of DNA. It was ﬁrst described by Notomi et al.
[41] and has to date been pursued for diagnosis of several
diseases. LAMP has been applied to detection of HAT in
several studies, starting with that targeting the Para-Flagellar
Rod protein A (PFR A), which is diagnostic for T. brucei.I n
that study analytical sensitivity of up to 100 times compared4 Journal of Tropical Medicine
(a) (b)
Figure 1: (a) the Primo Star iLED microscope has a UV light source that is beamed onto the slide from above, in addition to the classical
white light from below, with a knob for interchange between UV and white light. (b) in presence of UV light, acridine orange stained
trypanosomes ﬂuoresce against a dark background, making it easy to detect the parasites.
(a) (b)
Figure 2: (a) sample Oligo-C test produced for diagnosis of HAT or Leishmaniasis by Coris Bioconcept. (b) results of NASBA-OC on T. b.
rhodesiense cases from Eastern Uganda. Extreme left and right are the positive and negative controls, respectively. The 2 samples next to the
positive control were clearly positive.
to the PCR was reported [42]. Subsequently, Thekisoe et
al. [43] described LAMP targeting the 5.8S rRNA-internal-
transcribed spacer 2 (ITS2) gene for detection of T. b.
gambiense, reporting analytical sensitivity of up to 0.01
trypanosome in the tested sample. The following year,
Njiru et al. [44] published LAMP that ampliﬁes the random
insertion mobile element (RIME) that is diagnostic of the
subgenus Trypanozoon. The sensitivity observed was 0.001
trypanosomes/mL,thankstothehighcopynumberofRIME,
reportedly 500 copies/haploid genome [45]. Subsequent
work was targeted to the serum resistance-associated (SRA)
gene that is speciﬁc for T. b. rhodesiense; the resultant
LAMP test could detect 10 trypanosomes/mL of blood
[46]. Subsequently, RIME- and SRA-LAMP were compared
to SRA PCR for detection of DNA from T. b. rhodesiense
patients spotted on Flinders Technology Associates (FTA)
cards and stored for up to 2 years, where LAMP displayed
superior sensitivity [34]. Most recently, LAMP for detection
of T. b. gambiense has been described [47]. Despite the
ultrasensitive nature of LAMP, the only shortcoming is
that most assays rely on indirect methods for detection of
ampliﬁcation products. For this, several formats are available
ranging from DNA intercalating dyes to measurement of
turbidity. Comparative evaluation of some of them [48]
indicates that their correct interpretation can vary, and
the results could therefore be subjective. Thus, the ultra
sensitivity of LAMP could be compromised by inappropriate
visualisation of products. As a solution to this, Njiru [49]
has recently devised a lateral ﬂow test that speciﬁcally detects
genuine ampliﬁcation products (Figure 3).
Among the recently devised molecular tests, LAMP
has highest prospects for application at or nearest to theJournal of Tropical Medicine 5
(a)
Control line
Test line
(b)
Figure 3: (a) visualisation LAMP products by ﬂuorescence. To the extreme left and right are the negative and positive controls respectively.
The 2 samples next to the negative control were from T. b. rhodesiense HAT cases, the one next to positive control is from a non-HAT
infected individual. (b) detection of RIME LAMP ampliﬁcation product using doubled labelled Milenia Genline Hybridetect 2 lateral ﬂow
strips. Product detection is achieved through hybridisation of ﬂuoresceine isothiocyanate (FITC)-labeled probe with biotinylated LAMP
product followed by combination with gold-labeled anti-FITC forming a triple-labeled complex which moves up the strip and is captured
by an immobilized biotin-binding protein (test line). The nonhybridized FITC probe binds to the gold-labeled anti-FITC to form a double
complex without biotin and is trapped at the control line. The faint line between the test control lines is nonspeciﬁc binding at DIG test line.
treatment centre. It requires just a water bath or heating
block that can be maintained at 60–65◦C for 30–40
minutes, and the results can be readily visualised by naked
eye. Besides, there is no need for the elaborate template
puriﬁcation methods that are a must for PCR and NASBA.
Because of these advantages, the future of LAMP as a
point-of-care test is presently being pursued by FIND. This
test will be useful for screening and possibly also as a test
of cure that could shorten the mandatory 18–24 month
posttreatment follow-up period. A prototype LAMP kit for
HAT was launched by Eiken Chemical Company in Japan in
July 2011 and performance evaluation studies at treatment
centers spearheaded by FIND are ongoing.
9. The Quest for HAT Biomarkers
Biomarkers for HAT have gained attention over the past
decade. They stand a good chance of being exploited to
develop tests that would not require the cold chain so they
can have wide penetration to the treatment centres. The
formats of choice would be dipsticks or lateral ﬂow tests
that would provide results within minutes of application of
the sample. Such tests that involve limited or noninvasive
means to obtain the test sample will be most successful.
The ultimate aim should be to remove the requirement
for the dreaded lumbar puncture that is presently a major
obstacle to treatment seeking and followup. The search
for HAT biomarkers has been explored from 3 fronts:
biomarkers for disease severity, staging, and tests of cure.
Biomarkers for disease severity have been pursued with the
aim of identifying immunological responses that exacerbate
infection or soluble products from the trypanosomes that
directly contribute to pathology. The aim here would be to
identifythoseinordertodesignmoleculesthatcouldbeused
to oﬀer supportive treatment with a view to facilitate patient
r e c o v e r y .M o r t ye ta l .[ 50], for example, demonstrated that
administration of trypanosomal oligopeptidase inhibitors
improved the survival rate of mice infected with T. b. brucei.
Similarly, Mamani-Matsuda et al. [51] used quercetin and
found that it induced dose-dependent decreases in the levels
of TNF-α and nitric oxide and induced actual death of the
parasites. Nitric oxide is among the products of activated
human macrophages and contributes to central nervous
system pathology in late stage HAT via its toxic derivatives
or the ensuing oxidative stress.
10. Biomarkers for HAT Staging
Biomarkers for disease staging have been applied for decades
despite presence of a limited number of known candidates.
These are elevated CSF protein and white cell counts that
have traditionally been used in addition to actual demon-
stration of the trypanosomes. Subsequently, the observed
raised IgM in late-stage HAT was exploited to develop a
Latex IgM test that can be used for staging [52]. Later work
has explored inﬂammation-related proteins and markers of
brain damage in the CSF with the belief that these should
be elevated upon invasion of the brain compartment by
the trypanosomes. Indeed Hainard et al. [53] demonstrated
that a combination of CXCL10 (a 10kDA interferon-gamma-
induced protein, also known as IP-10), CXCL8 (Interleukin-
8) and H-FABP (heart fatty acid binding protein) identiﬁes
late-stageHATwith97%and100%sensitivityandspeciﬁcity
respectively. To this list of markers have been added osteo-
pontin and β-2-microglobulin [54], matrix metalloprotease
9, and intercellular adhesion molecule 1 [55]a sw e l la s
neopterin (Tiberti et al., man in prep). These markers are
all arrived at after analysing CSF, meaning that the lumbar
puncture still has to be performed if they can be used
as markers for staging. The future direction of research
should be investigating which of the identiﬁed markers are
elevatedinplasmaoflatestagepatientsaswell,althoughlittle
promise so far has been obtained from the few candidates
investigated in that context. Other ﬂuids that do not involve
any invasive sampling such as saliva, tears and urine should
be investigated. Hardly any attention has to date been given
to these. But Lejon et al. [56] previously demonstrated that
trypanosome antibodies could be detected from saliva of6 Journal of Tropical Medicine
HAT patients, indicating that noninvasive diagnosis of HAT
is a possibility.
11. Molecular Diagnosticsas Tests of Cure
The major obstacle facing national HAT control programs
is the long posttreatment followup to conﬁrm cure. In
principle, all treated patients must return every 6 months for
a period of 18–24 months for parasitological diagnosis to be
carried out and trace any persisting trypanosomes, particu-
larly in the CSF. The requirement for a lumbar puncture at
every followup visit is a disincentive for patients to return,
while the few willing to return may be deterred by the long
distances they have to cover to reach the treatment center.
Thus, without active case follow-up that is in itself very
expensive, big proportions of treated patients never return
for medical consultation. With this obstacle it is diﬃcult to
accurately determine the success on any control program,
given that chemotherapy is the mainstay in this endeavor.
Thus, any advance that points to tests that eliminates the
lumbar puncture or at least reduce their frequency may be a
big boost to followup. This might be achieved by application
of ultrasensitive techniques to detect nucleic acids, other
antigensofparasiteoriginorevenhostfactors.Deborggraeve
et al. [57] recently evaluated the PCR as a possible tool for
followup. They demonstrated a poor sensitivity to detect
relapsing patients by testing blood, while 20% of individuals
declared as successfully cured by conventional parasitology
still had signals indicative of trypanosome DNA in their
CSF. This may mean that PCR in such a case is just acting
as a measure of the rate of parasite DNA clearance from
circulation, that the latter continues to diminish from blood
even when live trypanosomes still exist in the CSF. Detection
ofDNAin CSF ofcuredpatients upto 2yearsaftertreatment
means that the relatively stable nature of DNA in this case
acts as a disadvantage such that DNA targeting techniques
mightnotbeusefulinfollowup.Theremainingoptioninthis
case would be to investigate RNA targeting diagnostics such
asNASBA-OC. Given its relativelylessstablenature, it would
be more likely that any observed signals emanate from RNA
that has presently or just recently been transcribed from live
trypanosomes.CouldtheobservationofdwindlingDNAsig-
nals in blood of relapsing patients imply that trypanosomes
that colonize the CSF never relocate backwards into the
bloodstream? For it is generally believed that all available
treatment regimens possibly attain drug concentrations in
blood that are way above the eﬀective doses, and that the
“resistant” trypanosomes are favored to survive in CSF
where just a fraction of the drug, concentrations observed
in blood are able to establish. Some evidence to support
this “one way” traversal comes from the observation that
in melarsoprol relapse patients, trypanosomes are almost
e x c l u s i v e l yo b s e rv e do n l yi nC S F[ 58, 59]. We have also made
a similar observation in patients relapsing after eﬂornithine
(Matovu et al., manuscript in preparation). Alternatively it
is possible that they relocate but fail to reestablish in blood,
given that their traversal in CSF is facilitated by massive
adaptations to this relatively poor medium to the extent that
they may fail to cope when they return to the blood system.
This is surprisingly not the case in the mouse model, where
trypanosomeshidinginthebrainwerereportedtorecolonize
the blood system after treatment [60].
12. Biomarkers asTests of Cure
Another option to consider for tests of cure are biomarkers,
if candidates that drastically and consistently diminish from
circulation after successful treatment can be identiﬁed.
Several attempts have been made in this direction. Lejon
et al. [61, 62] demonstrated that CSF cells, IL-10, IgM,
and protein concentration all remain elevated in relapsing
patients,whiletheycontinuetodeclineinsuccessfullytreated
individuals. In a similar study, Ngoyi et al. [63] proposed
an algorithm for reducing the follow-up duration that also
combines determination of CSF IgM and white cell counts.
Obviously, it would be added advantage if such markers can
be traced in blood or noninvasively from other body ﬂuids.
13. Conclusions and Way Forward
There are some recent advances towards identiﬁcation of
candidates that could be used to develop point-of-care
diagnostics and staging tools. However, this area of research
has advanced at a rather slow pace despite the known fact
that accurate diagnosis is key to the success of any HAT
control program. Even at this point when we can imagine
elimination of HAT as a possibility in some regions, highly
sensitive and widely applicable diagnostic tools will be at the
centre of any such attempt. High precision diagnostics are
required to screen the entire populations in order to ﬁsh out
the last cases or animal reservoirs. It is surprising that since
the development of the CATT in the late 1970s, only one
potential replacement has been developed. The lateral ﬂow
Rapid Diagnostic Test (RDT) that has just been developed is
now undergoing evaluation in some T. b. gambiense endemic
countries(seehttp://www.ﬁnddiagnostics.org/programs/hat/
ﬁnd activities/serodiagnosis.html). The other report is an
attemptimprovetheCATTbydevelopmentofsyntheticpep-
tides [64] to use in the place of native antigens that tend to
cross-react, giving the characteristic false positives associated
with the test. Meanwhile, a serological screening test for T. b.
rhodesiense is still missing.
Therefore, much as recent attempts to identify biomark-
ers and genomic sequences to exploit for new diagnostics
should be appreciated, there is much more eﬀort required if
we are to realize continued HAT suppression. As mentioned
elsewhere, the current needs are not only novel point of care
diagnostics, but also those that can eliminate the need for
a lumbar puncture should be given priority. It should be
borne in mind that staging will be required for as long as
there is no safe drug that is eﬀective against both stages of
the disease. Thus, patients who shun followup because of
the lumbar puncture remain potential reservoirs from which
trypanosomes that have been exposed to treatment can be
transmitted, thereby spreading drug resistance.Journal of Tropical Medicine 7
The new ﬂuorescence LED microscopy and the possi-
bility to concentrate blood much more eﬀectively than ever
before are good developments in demonstration of parasites
in cases with extremely low parasitaemia. Their evaluation
in T. b. gambiense areas needs to be expedited to show if
incidences of the so-called aparasitaemic cases [65]c a n
be curbed. At the same time, hand-held prototypes built
with similar technology as the LED microscope should be
explored, as they would allow for wider coverage of the
diagnostic services. Lastly, the need for an RDT type capable
of detecting T. b. rhodesiense cannot be over emphasized.
Actually,thisonitsowncanbearguedtobetheonlyobstacle
hindering elimination of the acute form of HAT.
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